End-Payors, Direct Purchasers Get Cert. In Solodyn MDL

Law360, New York (October 16, 2017, 11:22 PM EDT) -- End-payor and direct purchasers' bids for class certification were granted in Massachusetts federal court Monday in the pay-for-delay litigation against drugmakers Medicis Pharmaceutical Corp. and Impax Laboratories Inc. over the generic version of Medicis' acne medication Solodyn.

U.S. District Judge Denise J. Casper certified a class of direct buyers of the drug, as well as a class of consumers who said Impax and other companies colluded with Medicis to limit Solodyn's competition, in turn keeping the drug's price high.

Judge Casper rejected the drugmakers' argument that direct purchaser class members should be consolidated based on corporate structure in an attempt to show...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!